Advertisement

Optimal management of major bleeding on DOACs: not only reversal agents

  • Silvia Galliazzo
  • Alessandro SquizzatoEmail author
IM - COMMENTARY
  • 44 Downloads

Direct oral anticoagulants (DOACs) are currently prescribed in more than 50% of patients affected by non-valvular atrial fibrillation (FANV) or venous thromboembolism [1, 2]. Data from post-marketing studies confirmed the favourable risk–benefit profile of DOACs when compared with vitamin K antagonist (VKA) [3, 4]. However, all anticoagulant drugs carry an intrinsic unavoidable bleeding risk. Although rare, major and life-threatening bleedings required a timely management, given their high case-fatality rate and potential morbidity. Well-defined and widely available management protocols are crucial to address these emergency situations without delay. The development of a first reversal agent, e.g., idarucizumab, opened the new era of DOAC-specific antidote to restore haemostasis on time. As Andexanet alpha is not licensed in many countries, factor Xa inhibitors’ reversal can be rapidly managed by bypass-agents, mainly prothrombin complex concentrate (PCC) [5]. Despite four-factor PCC...

Notes

Compliance with ethical standards

Conflict of interest

Alessandro Squizzato received fees for lectures and/or advisory board meetings from Daiichi Sankyo, Pfizer, Bristol Myers Squibb, Bayer, Boehringer Ingelheim. Silvia Galliazzo, nothing to disclose.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY, GLORIA-AF Investigators (2017) The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol 69(7):777–785CrossRefGoogle Scholar
  2. 2.
    Ageno W, McCallun P, Haas S, Weitz JI, Angchaisuksiri P, Bounameaux H, Goldhaber SZ, Goto S, Kayani G, Dalsgaard Nielsen J, Mantovani LG, Schellong S, Turpie AGG, Prandoni P, Kakkar AK. Clinical characteristics and management of 10,329 patients with a confirmed diagnosis of venous thromboembolism: the GARFIELD-VTE registry. Abstract ASY 35.4, ISTH 2017Google Scholar
  3. 3.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962CrossRefGoogle Scholar
  4. 4.
    van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR (2014) Directoral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968–1975CrossRefGoogle Scholar
  5. 5.
    Testa S, Ageno W, Antonucci E, Morandini R, Beyer-Westendorf J, Paciaroni M, Righini M, Sivera P, Verhamme P, Pengo V, Poli D, Plareti G (2018) Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Intern Emerg Med 13:1051–1058CrossRefGoogle Scholar
  6. 6.
    Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, Crowther MA, Agarwal A, Bhatt M, Khatib R, Riva JJ, Zhang Y, Guyatt G (2108) American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2(22):3257–3291  CrossRefGoogle Scholar
  7. 7.
    Sheikh-Taha M (2018) Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate. Intern Emerg Med.  https://doi.org/10.1007/s11739-018-1977-9
  8. 8.
    Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694CrossRefGoogle Scholar
  9. 9.
    Khorsand N, Majeed A, Sarode R, Beyer-Westendorf J, Schulman S, Meijer K, Subcommittee on Control of Anticoagulation (2016) Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH. J Thromb Haemost 14(1):211–214CrossRefGoogle Scholar
  10. 10.
    Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, ANNEXA-4 Investigators (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  1. 1.Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Medicine and Surgery, School of MedicineUniversity of InsubriaVareseItaly

Personalised recommendations